Treatment of Epstein-Barr Virus infection in immunocompromised patients.
Pociupany M, Snoeck R, Dierickx D, Andrei G.
Biochem Pharmacol. 2024 Jul;225:116270. doi: 10.1016/j.bcp.2024.116270. Epub 2024 May 10.
Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR.
J Clin Pathol. 2019 Oct;72(10):651-658. doi: 10.1136/jclinpath-2019-205822. Epub 2019 Jul 17.
Epstein-Barr Virus and Systemic Autoimmune Diseases.
Houen G, Trier NH.
Front Immunol. 2021 Jan 7;11:587380. doi: 10.3389/fimmu.2020.587380. eCollection 2020.
[EB virus infection].
Kawa K.
Nihon Rinsho Meneki Gakkai Kaishi. 1996 Dec;19(6):583-7.
Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications.
Bjornevik K, Münz C, Cohen JI, Ascherio A.
Nat Rev Neurol. 2023 Mar;19(3):160-171. doi: 10.1038/s41582-023-00775-5. Epub 2023 Feb 9.
Epstein-Barr virus-associated gastric cancer: A distinct subtype.
Yang J, Liu Z, Zeng B, Hu G, Gan R.
Cancer Lett. 2020 Dec 28;495:191-199. doi: 10.1016/j.canlet.2020.09.019. Epub 2020 Sep 23.
Virus-triggered secondary hemophagocytic lymphohistiocytosis.
Imashuku S, Morimoto A, Ishii E.
Acta Paediatr. 2021 Oct;110(10):2729-2736. doi: 10.1111/apa.15973. Epub 2021 Jun 22.
Clinical syndromes associated with EB virus infection.
Evans AS.
Adv Intern Med. 1972;18:77-93.
How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection.
Bu GL, Xie C, Kang YF, Zeng MS, Sun C.
Viruses. 2022 Oct 27;14(11):2372. doi: 10.3390/v14112372.
[A case of facial diplegia due to EB virus infection].
Matsushima K, Shinohara Y, Yamamoto M.
Rinsho Shinkeigaku. 1990 Sep;30(9):1013-6.
